Status:
COMPLETED
Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This study is being carried out to see if quetiapine (Seroquel) is effective in preventing patients from a schizophrenic relapse when studied for a long time (1 year) and if so, how it compares with n...
Eligibility Criteria
Inclusion
- Stable schizophrenic patients who have provided written informed consent
- Patients 18 to 65 years old who remain clinically stable after switching to a stable dose of Seroquel (quetiapine).
Exclusion
- Patients with risk of suicide, other disorders or substance abuse that might interfere with the patient's ability to co-operate,
- Expected non-compliance to treatment
- Known diabetes mellitus,
- Contraindications,
- Intolerance or non-responsiveness to Seroquel or other safety issues.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT00228462
Start Date
March 1 2005
End Date
April 1 2006
Last Update
January 4 2013
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Burgas, Bulgaria
2
Investigative Site
Radnevo, Bulgaria
3
Investigative Site
Sofia, Bulgaria
4
Investigative Site
Bydgoszcz, Poland